Table 1.
Baseline characteristics.
| Characteristics | N = 30 |
|---|---|
| Age (years), median (range) | 32.5 (19.0–67.0) |
| Sex, n (%) | |
| Male | 16 (53.33) |
| Female | 14 (46.67) |
| ECOG performance status, n (%) | |
| 0 | 24 (80.00) |
| 1 | 6 (20.00) |
| Histology, n (%) | |
| ASPS | 12 (40.00) |
| Synovial sarcoma | 7 (23.33) |
| UPS | 5 (16.67) |
| Leiomyosarcoma | 4 (13.3) |
| Fibrosarcoma | 1 (3.33) |
| Epithelioid sarcoma | 1 (3.33) |
| Stage, n (%) | |
| IV | 30 (100.00) |
| Others | 0 |
| Brain metastasis, n (%) | |
| Yes | 1 (3.33) |
| No | 29 (96.67) |
| Liver metastasis, n (%) | |
| Yes | 4 (13.33) |
| No | 26 (86.67) |
| Lung metastasis, n (%) | |
| Yes | 24 (80.00) |
| No | 6 (20.00) |
| Another metastasis, n (%) | |
| Yes | 9 (30.00) |
| No | 21 (70.00) |
| Surgical history, n (%) | |
| Yes | 27 (90.00) |
| No | 3 (10.00) |
| Previous chemotherapy, n (%) | |
| Yes | 22 (73.33) |
| No | 8 (26.67) |
| Previous radiotherapy, n (%) | |
| Yes | 6 (20.00) |
| No | 24 (80.00) |
| Previous systemic therapy, n (%) | |
| First-line | 16 (53.33) |
| Second-line | 5 (16.6) |
| Third-line | 1 (3.33) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.